- Previous Close
66.41 - Open
67.70 - Bid 66.64 x 100
- Ask 67.42 x 100
- Day's Range
66.42 - 68.41 - 52 Week Range
40.62 - 79.62 - Volume
220,121 - Avg. Volume
2,634,940 - Market Cap (intraday)
12.388B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.95 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
79.01
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
www.exactsciences.com6,500
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: EXAS
View More
Performance Overview: EXAS
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXAS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXAS
View MoreValuation Measures
Market Cap
12.27B
Enterprise Value
14.09B
Trailing P/E
--
Forward P/E
2.00k
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.63
Price/Book (mrq)
3.84
Enterprise Value/Revenue
5.39
Enterprise Value/EBITDA
203.32
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.70%
Return on Assets (ttm)
-2.71%
Return on Equity (ttm)
-5.60%
Revenue (ttm)
2.61B
Net Income Avi to Common (ttm)
-175.01M
Diluted EPS (ttm)
-0.95
Balance Sheet and Cash Flow
Total Cash (mrq)
946.78M
Total Debt/Equity (mrq)
87.21%
Levered Free Cash Flow (ttm)
-574.75k
Research Analysis: EXAS
View MoreCompany Insights: EXAS
EXAS does not have Company Insights
Research Reports: EXAS
View MoreExact Sciences Has an Established Colon Cancer Screening Franchise With Progressing Pipeline
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
RatingPrice TargetExact Sciences Earnings: Shares Still Undervalued on Inline Results as Profit Margins Improve
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
RatingPrice TargetExact Sciences Earnings: Shares Still Undervalued on Inline Results as Profit Margins Improve
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
RatingPrice TargetExact Sciences Earnings: Below Expectations but No Impact on Long-Term Story, Shares Undervalued
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
RatingPrice Target